Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ALX2004

Antibody-drug conjugate · Cytotoxic, directed at epidermal growth factor receptor (EGFR) · developed by ALX Oncology

Phase 1 Most advanced trial

ALXO Developer

1 Registered trials

What is ALX2004?

ALX2004 is an antibody-drug conjugate that pairs an Fc-active monoclonal antibody binding EGFR with a topoisomerase I inhibitor linked by a cleavable linker. It is being studied in non-small cell lung cancer, head and neck squamous cell carcinoma, colorectal cancer, and esophageal squamous cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Antibody-drug conjugate
Targets: epidermal growth factor receptor (EGFR), DNA topoisomerase I (TOP1) (secondary target)
Mechanism: Cytotoxic, directed at epidermal growth factor receptor (EGFR)
Pathways: EGFR-mediated signaling inhibition, DNA replication inhibition, cell cycle arrest and apoptosis, bystander killing, immunogenic cell death
Therapy area: Oncology
Developer: ALX Oncology Inc. (ALXO)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07085091	Phase 1	NSCLC (Advanced Non-small Cell Lung Cancer)	Recruiting	ALXO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Colo-rectal CancerCRC (Colorectal Cancer)ESCCEsophageal Squamous Cell Carcinoma (ESCC)Head and Neck CancerHNSCCNSCLC (Advanced Non-small Cell Lung Cancer)

Other drugs acting on EGFR

Neratinib FDA approved Osimertinib FDA approved Actinium Ac 225 FPI-2068 Phase 1 BH-30643 Phase 1/2 CUDC-101 Phase 1 EGFR-TKI inhibitor based on investigator's choice Phase 3 Enozertinib Phase 1/2 Ficerafusp Alfa Phase 2/3 Firmonertinib Phase 3 FPI-2053 Phase 1 Izalontamab Brengitecan Phase 2/3 Silevertinib Phase 1/2

More from ALX Oncology

Evorpacept Phase 2/3

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ALXO page.

Follow ALXO, the company behind ALX2004

See ALXO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALXO catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z